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Background/aim: This study was designed to evaluate the relationship between urinary phytate concentration and risk of fracture at
10 years, determined by using the FRAX model, in women who had undergone menopause within 5 years of the time of enrollment.
Materials and methods: Of the 212 postmenopausal women evaluated, 69 were excluded because they had urinary phytate concentrations
between 0.51 and 0.99 mg/L. Of the remaining 143 women, 91 had low (≤0.50 mg/L) and 52 had high (≥1.0 mg/L) urinary phytate
concentrations. The 10-year risk of fracture was calculated by using the FRAX model.
Results: The risks of major osteoporotic fracture and hip fracture were higher in women with low urinary phytate levels (P < 0.001 in
both cases). Evaluation of the risk of hip fracture in women with and without risk factors for osteoporosis (e.g., tobacco, alcohol, and
drug consumption) and according to urinary phytate concentrations indicated that, among women with no risk factors, those with low
and high urinary phytate levels had a range of risks of 0%–0.6% and 0%–0.3%, respectively (P = 0.098). Moreover, among women with at
least one risk factor, those with low and high urinary phytate had a range of risks of 0.1%–0.8% and 0.1%–0.4%, respectively (P = 0.002).
Similar results were observed when the risks of major osteoporotic fracture were analyzed.
Conclusion: These results indicate the relationship of phytate with the risks of major osteoporotic fracture and hip fracture, with these
differences being more marked in women with risk factors for osteoporosis. From this study follows the importance of the consumption
of phytate-rich products (nuts, legumes, whole cereals) to protect against the risk of fracture in 10 years, mainly in women with risk
factors for osteoporosis.
Key words: Phytate, postmenopausal women, fracture risk, FRAX index, hip fracture

1. Introduction
Osteoporosis has been defined as a skeletal disease
characterized by reduced bone strength, thereby
predisposing individuals to an increased risk of fracture
(1). Bone strength can be determined by measuring the
bone density (in grams of mineral per unit area or volume)
and the properties of bone and tissue, including its macroand microarchitecture. However, reduced bone strength is
not the only factor predictive of the risk of fracture, with
several factors not associated with bone being predictive of
the risk of fracture.
Based on observational studies, various clinical practice
guidelines have concluded that the most important risk
factors in the development of fractures include personal
history of a fragility fracture, defined as a spontaneous

fracture during adult life or a fracture caused by trauma
that would not have occurred in a healthy individual; age
≥65 years; history of fragility fracture in at least one firstgrade relative; low body mass index (BMI; <20 kg/m2); and
glucocorticoid treatment (2–4). High risk factors include
falling in the previous year, hypoparathyroidism, eating
disorders, and chronic malnutrition and malabsorption.
Moderate risk factors include female sex; early menopause,
at age 40–45 years; consumption of >3 units of alcohol/day;
being a current smoker; and having insulin-dependent
diabetes, rheumatoid arthritis, or hyperthyroidism.
Risk of fracture is associated with bone mineral density
(BMD). Dual-energy X-ray absorptiometry (DXA) has
been found to be optimal in measuring BMD of the
spine and hips to predict the risk of fracture (4,5). The
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combination of clinical risk factors for fragility fracture
with measurement of BMD by central DXA has been
shown to be the most effective predictor of the risk of
fracture (2).
The FRAX model is an assessment tool for fracture
risk in men and women aged 40–90 years (6). Model
algorithms using computer programs that calculate the
10-year probabilities of overall brittle fractures and hip
fractures have been developed for 12 countries: Austria,
China, France, Germany, Italy, Japan, Spain, Sweden,
Switzerland, Turkey, the United Kingdom, and the United
States (with specific models for persons of Caucasian,
African American, Latino, and Asian ethnicities). These
models have been validated in cohort studies and found
to be accurate in predicting the 10-year risks of overall and
hip fractures.
Myo-inositol hexaphosphate, also called phytic
acid and phytate, is a molecule abundant in vegetable
seeds, like legumes, nuts, and whole cereals (7). Phytate
constitutes 1.5%–6.4% of the dry weight of grains and is
mostly bound to calcium and magnesium ions (7). Phytate
is also found in mammalian tissues and organs at levels
dependent on dietary intake (8), with correlations between
concentrations in plasma and urine (9). Phytate, which
acts as an antioxidant, has been found to affect human
health (7). For example, phytate has beneficial effects on
renal lithiasis (10,11), sialolithiasis (12), tartar (13), and
cardiovascular calcifications (14–16). Moreover, phytate
apparently has protective effects against osteoporosis (1720). Therefore, this study evaluated the relationship of
phytate with fracture risk as assessed by the FRAX index.
2. Materials and methods
2.1. Participants
This descriptive cross-sectional pilot study included 212
postmenopausal women from Majorca (Balearic Islands).
Subjects were evaluated with in-depth clinical interviews,
including whether or not they had entered menopause; in
the case of doubt, hormone concentrations were measured.
Personal and clinical data were collected by GESMA’s
Occupational Health Service. The study protocol was
approved by the Balearic Research Ethics Board (Protocol
#IB 1027/08 PI). Considering our previous experience
related to urinary phytate levels, the participants in the
present study were divided into three groups: one with
low urinary phytate levels (≤0.5 mg/L); one with medium
urinary phytate levels (0.51–0.99 mg/L), which were
excluded; and one with high urinary phytate levels (≥0.99
mg/L). Criteria for inclusion and exclusion are shown in
Table 1.
2.2. Urine samples and phytate analysis
All women consumed an unrestricted diet during the
sample collection period. A urine sample was collected

from each volunteer. Two hours after the first urine of the
morning, a fasting urine sample was collected, stored at 4
°C, and transported to the laboratory in a chilled container.
Phytate concentrations were immediately analyzed as
described (21). The method used to determine phytate
is nonspecific, so in addition to inositol hexaphosphate
(Insp6) it can also include the determination of other
lower inositol phosphates (InsP5, InsP4, etc.) (7).
2.3. Determination of bone mineral density
BMD of the femoral neck was determined by DXA
(Norland Excell bone densitometer, MEC Osteoporosis
Bone Densitometry, Minster, OH, USA) and is reported as
g/cm2. All densitometry measurements were performed by
a single technician to avoid interobserver bias.
2.4. Evaluation of fracture risk using FRAX
Demographic and clinical data collected included patient
age; parental history of osteoporotic hip fracture; personal
history of fragility fracture; current consumption of
tobacco; consumption of 3 or more units/day of alcohol,
with each unit defined as 8–10 g of alcohol; rheumatoid
arthritis; and use of oral corticosteroids for more than 3
months (≥5 mg/day of prednisolone or equivalent doses of
other glucocorticoids).
Factors associated with secondary osteoporosis were
also recorded, including histories of type 1 diabetes,
imperfect osteogenesis in adults, untreated chronic
hyperthyroidism, hypogonadism, early menopause (before
45 years of age), chronic malnutrition, malabsorption, and
chronic liver disease. Weight and height were determined
by approved and calibrated scales and BMI was calculated.
The FRAX index for each subject was calculated using a
computer tool available online for the Spanish population
(22). The 10-year probabilities of hip fracture and of major
osteoporotic fractures, defined as the sum of clinical
vertebral, forearm, hip, and proximal humerus fractures,
were calculated.
2.5. Statistics
Normality of the data was assessed by the Kolmogorov–
Smirnov test and plotting of histograms and Q-Q graphs.
As the majority of the data were not normally distributed,
continuous variables were expressed as medians and
interquartile ranges, or ranges (minimum and maximum
values). Between groups, the differences were assessed by
the Mann–Whitney U test. Risks and qualitative variables
were expressed as percentages. Qualitative variables were
compared between groups using the chi-square test. All
statistical analyses were performed using SPSS 22 for
Windows.
3. Results
Of the 212 women evaluated, 69 had urinary phytate
concentrations between 0.51 and 0.99 mg/L and were
excluded. Of the remaining 143 subjects, 91 had low
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(≤0.50 mg/L) and 52 had high (≥1.0 mg/L) urinary
phytate concentrations. The demographic and clinical
characteristics of these groups are shown in Table 2. Of the
factors analyzed, only BMD of the femoral neck differed
significantly in the two groups.
The 10-year risk of hip fracture was significantly higher
in subjects with low than with high urinary phytate levels
(ranges: 0%–0.8% and 0%–0.4%, P < 0.001; Figure 1A).
Similarly, the 10-year risk of major osteoporotic
fractures (proximal humerus, clinical vertebral forearm,
hip) were significantly higher in subjects with low than
with high urinary phytate levels (ranges: 0.8%–4.5% and
0.8%–3.8%, P < 0.001; Figure 1B).
Evaluation of the risk of hip fracture in women with
and without risk factors for osteoporosis (e.g., tobacco,

alcohol, and drug consumption) and according to urinary
phytate concentrations showed that, among women with
no risk factors, those with low and high urinary phytate
levels had a range of risks of 0%–0.6% and 0%–0.3%,
respectively (P = 0.098; Figure 2). Moreover, among
women with at least one risk factor, those with low and
high urinary phytate had a range of risks of 0.1%–0.8%
and 0.1%–0.4%, respectively (P = 0.002; Figure 2).
In the same way, evaluation of the risk of major
osteoporotic fractures in women with and without risk
factors for osteoporosis and according to urinary phytate
concentration showed that, among women with no risk
factors, those with low and high urinary phytate levels had
a range of risks of 0.8%–3% and 0.8%–2.3% respectively
(P = 0.041; Figure 3). Moreover, among women with

Table 1. Criteria for subjects’ acceptance into the study.
Inclusion criteria

Exclusion criteria

Female sex

>5 years since menopause

Occurrence of menopause
Surgical menopause
Agreement to participate in the study and provision of informed Treatment with bisphosphonates or other drugs used to treat
consent
osteoporosis
Urinary phytate concentrations between 0.51 and 0.99 mg/L

Table 2. Demographic and clinical characteristics of postmenopausal women with low and high urinary phytate
concentrations.
Low urinary phytate (≤0.5 mg/L)a High urinary phytate (≥1.0 mg/L)a P-valueb
Age (years)

52 (4)

51 (5)

0.389

Weight (kg)

65.0 (9)

64.5 (9)

0.807

Height (cm)

160 (8)

161 (8)

0.987

BMI (kg/m2)

24.7 (4.2)

24.6 (4.2)

0.906

Years since menopause

3 (1)

4 (2)

0.252

BMD femoral neck (g/cm2)

0.72 (0.14)

0.84 (0.14)

<0.001

Fracture history (%)

19.8

17.3

0.716

Tobacco consumption (%)

30.8

34.6

0.636

Glucocorticoids (%)

5.5

5.8

0.945

Alcohol (%)

12.1

11.5

0.922

7.7

0.820

Secondary causes of osteoporosis (%) 8.8

Median (interquartile range) or percentage.
Comparison of low and high urinary phytate groups. Mann–Whitney U test or chi-square test.

a

b
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Figure 1. Box-plots for (A) 10-year risk of hip fracture and (B) 10-year risk of major osteoporotic fracture, relative to urinary phytate
concentration.

Figure 2. Box-plots for 10-year risk of hip fracture relative to urinary phytate
concentrations and presence or absence of risk factors for osteoporosis.

at least one risk factor, those with low and high urinary
phytate had a range of risks of 1.1%–4.5% and 1.0%–3.8%,
respectively (P = 0.005; Figure 3).
4. Discussion
Phytate consumption by postmenopausal women living on
Mallorca reduced their risks of hip and major osteoporotic
fractures, as calculated by the FRAX model. To the best of

our knowledge, the current assessment of the relationship
between urinary phytate and the risks of fracture in
postmenopausal women is the first study to examine this
link in any population, including other groups such as
nonmenopausal women and men.
Previous studies by our group showed a direct
relationship between the consumption of phytate, as
determined by food surveys, and increased BMD in
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Figure 3. Box-plots for 10-year risk of major osteoporotic fracture relative to urinary
phytate concentration and presence or absence of risk factors for osteoporosis.

the calcaneus, lumbar spine, and femoral neck in the
general population (17) and in postmenopausal women
(20). Similar results were observed when phytate
consumption was determined by measuring urinary
phytate concentrations (18) using an unspecific method
that evaluates the set of inositol phosphates, as well as in
ovariectomized rats (19). Another study found that bone
loss in postmenopausal women was lower in the group of
women that consumed greater amounts of phytate (20).
The classification of participants according to low urinary
phytate (<0.5 mg/L), medium urinary phytate (0.51–
0.99 mg/L), and high urinary phytate (<0.99 mg/L) is a
consequence of the results obtained in the previous studies
that have been cited. The results of the present study
therefore provide further evidence that consumption of
phytate increases BMD, slows bone loss, and reduces the
risk of fractures at various locations in postmenopausal
women. Interestingly, these positive effects of phytate
consumption were greater in women with risk factors for
osteoporosis.
The effects of phytate are similar to those of some
bisphosphonates, which are chemically similar to phytate.
Phosphate and phosphonate groups have high affinities
for calcium crystal surfaces, thereby promoting self-
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adsorption and avoiding redissolution (23). In this aspect
it is important to note that the analytical method that
has been used to analyze phytate in urine is a nonspecific
method to evaluate inositol hexaphosphate (InsP6), and
also evaluates the presence of other inositol phosphates
(InsP5, InsP4, etc.), which, being polyphosphates, can also
play an important role in avoiding the redissolution of
hydroxyapatite, in a manner analogous to bisphosphonates.
These substances also reduce the activities of osteoclasts,
thereby protecting against bone reabsorption (24,25).
The main limitation of the present study was its
inclusion of only women with a maximum of 5 years since
menopause. The beneficial effects of phytate consumption
on bone mass and fracture risk should also be assessed in
other subjects, including women >5 years past menopause,
premenopausal women, and men.
In conclusion, phytate consumption by postmenopausal
women reduced their risks of hip and major osteoporotic
fractures, as calculated by the FRAX model. The positive
effects of phytate consumption were greater in women
with than without risk factors for osteoporosis. The main
limitation of the present study was the inclusion only of
women with a maximum of 5 years since menopause.
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